Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone?
Scherbaum
Werner A
WA
Department of Endocrinology, Diabetes and Rheumatology, University Hospital Düsseldorf and German Diabetes Center, Leibniz Center for Diabetes Research, Auf'm Hennekamp 65, D-40225 Düsseldorf, Germany. scherbaum@ddz.uni-duesseldorf.de
D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007249:Inflammation / Q000150:complications / Q000188:drug therapy; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use; D014511:Uremia / Q000097:blood / Q000150:complications / Q000628:therapy*; D015430:Weight Gain
D002097:C-Reactive Protein; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000077154:Rosiglitazone; D045162:Thiazolidinediones